[Treatment of hepatitis C virus-related cirrhosis].
Bronowicki
Jean-Pierre
JP
Service de Médecine Interne, Hôpital La Pitié-Salpêtrière, Paris.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D005355:Fibrosis; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008113:Liver Neoplasms / Q000517:prevention & control; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons